Sanofi(SNY)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SNY Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Sanofi (SNY), a Healthcare sector company. SNY is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of SNY by reported 13-F value include DODGE & COX, MORGAN STANLEY, Fisher Asset Management, based on the most recent SEC filings. SNY trades on the Nasdaq exchange and files with the SEC under CIK 1121404. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sanofi directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
-4.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $126.81B -4.5% | $132.80B +5.0% | $126.46B -0.2% | $126.72B +5.4% | $120.24B +5.1% | $114.41B |
Get alerted when SNY's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Sanofi including:
Top Institutional Holders of SNY
DODGE & COX
$1.2B28,088,274 shMORGAN STANLEY
$456.6M10,702,527 shFisher Asset Management, LLC
$453.4M10,627,088 shBANK OF AMERICA CORP /DE/
$341.6M8,008,572 shInvesco Ltd.
$290.0M6,798,961 shJPMORGAN CHASE & CO
$285.5M6,573,682 shMondrian Investment Partners LTD
$235.6M5,522,564 shBRANDES INVESTMENT PARTNERS, LP
$176.5M4,136,417 shFEDERATED HERMES, INC.
$164.2M3,849,802 shBoston Partners
$164.0M3,844,844 sh
| Fund | Value | Shares |
|---|---|---|
| DODGE & COX | $1.2B | 28,088,274 |
| MORGAN STANLEY | $456.6M | 10,702,527 |
| Fisher Asset Management, LLC | $453.4M | 10,627,088 |
| BANK OF AMERICA CORP /DE/ | $341.6M | 8,008,572 |
| Invesco Ltd. | $290.0M | 6,798,961 |
| JPMORGAN CHASE & CO | $285.5M | 6,573,682 |
| Mondrian Investment Partners LTD | $235.6M | 5,522,564 |
| BRANDES INVESTMENT PARTNERS, LP | $176.5M | 4,136,417 |
| FEDERATED HERMES, INC. | $164.2M | 3,849,802 |
| Boston Partners | $164.0M | 3,844,844 |
More Healthcare Companies
View all Healthcare →Put SNY on your watchlist
Track score changes the day Sanofi files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SNY a good stock to buy?
13F Pro's AI-powered analysis of Sanofi (SNY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNY are available on the SNY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SNY is classified as a large company.
Which hedge funds own SNY?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sanofi's investment landscape.